Abstract

Cytotrienin A, a member of the triene-ansamycin family, was initially identified to be an inducer of apoptosis and recently shown to be an inhibitor of translation that interferes with eukaryotic elongation factor 1A function. In human lung carcinoma A549 cells, cytotrienin A was found to inhibit more strongly the cell-surface expression of intercellular adhesion molecule-1 (ICAM-1) induced by tumor necrosis factor (TNF)-α than the expression induced by interleukin (IL)-1α. Cytotrienin A induced the ectodomain shedding of TNF receptor 1 by TNF-α-converting enzyme (TACE). The TACE inhibitor TAPI-2 antagonized the selective inhibitory effect of cytotrienin A on inhibitor of nuclear factor-κB-α (IκBα) degradation as well as ICAM-1 expression in TNF-α-stimulated cells. The MEK inhibitor U0126 and the p38 MAP kinase inhibitor SB203580, but not the JNK inhibitor SP600125, prevented the ectodomain shedding of TNF receptor 1 induced by cytotrienin A and reversed the inhibitory effects of cytotrienin A on the TNF-α-induced IκBα degradation. In the presence of both U0126 and SB203580, cytotrienin A inhibited TNF-α- and IL-1α-induced ICAM-1 expression at almost equivalent concentrations. Thus, our present results demonstrate that cytotrienin A is a translation inhibitor that triggers ribotoxic stress response and selectively inhibits the TNF-α-induced ICAM-1 expression by inducing the ectodomain shedding of TNF receptor 1 via the activation of ERK and p38 MAP kinase.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.